Arthur J. Moss, MD, known in the cardiology field for his extensive research in diagnosing and treating long QT syndrome (LQTS), died of cancer Feb. 14 at his home in Brighton, New York. He was 86.

The FDA announced on Feb. 26 a Class I recall for nine of Medtronic's cardiac resynchronization therapy with defibrillation (CRT-D) devices and 12 of its implantable cardioverter-defibrillators (ICDs). Due to a manufacturing defect, a gas mixture can enter the devices and hamper their ability to provide shock therapy.

The American Heart Association (AHA) believes an additional 50,000 lives per year could be saved if all hospitals in the United States adopted its Resuscitation Quality Improvement (RQI) program.

The clinical benefit patients gain from remote monitoring with implantable electronic devices far outweighs the risk of the devices being hacked, according to a paper published Feb. 20 by the American College of Cardiology’s Electrophysiology Council.

SANTA CLARA, Calif.—February 20, 2018—Cardiva Medical®, an innovator in the field of vascular closure, today announced that the company has closed on $11 million in additional financing — bringing total equity and debt financing in the current round to $41 million.

Longview Regional Medical Center in Texas co-hosted a “Play it Safe” event inviting teenagers across East Texas and surrounding areas to participate in free heart checkups. Now in its fifth year, the event was also hosted by Championship Hearts Foundation, a nonprofit that focuses on preventing sudden cardiac death among youth.

COPENHAGEN, February 8, 2018 — Acesion Pharma ("Acesion" or the Company), a Danish biotech company developing novel treatments for atrial fibrillation (AF), the most common cardiac arrhythmia, announces today it has received approval to commence its first clinical study for its lead compound AP30663. The phase 1 study in healthy subjects will be conducted at the Centre for Human Drug Research (CHDR) in the Netherlands and is due to start in March 2018.

For nearly 6,000 patients with heart failure and chronic kidney disease (CKD), the use of an implantable cardioverter defibrillator (ICD) showed no mortality benefit but a higher risk of subsequent hospitalizations after covariate adjustment, researchers reported in JAMA Internal Medicine.